[go: up one dir, main page]

WO2000061155A1 - Composition, contenant du soufre sublime, permettant de traiter l'intolerance au lactose - Google Patents

Composition, contenant du soufre sublime, permettant de traiter l'intolerance au lactose Download PDF

Info

Publication number
WO2000061155A1
WO2000061155A1 PCT/CA1999/000893 CA9900893W WO0061155A1 WO 2000061155 A1 WO2000061155 A1 WO 2000061155A1 CA 9900893 W CA9900893 W CA 9900893W WO 0061155 A1 WO0061155 A1 WO 0061155A1
Authority
WO
WIPO (PCT)
Prior art keywords
lactose
sublimed sulfur
patients
sulfur
milk
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/CA1999/000893
Other languages
English (en)
Inventor
Airudin S. Khan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CA 2265921 external-priority patent/CA2265921C/fr
Application filed by Individual filed Critical Individual
Priority to AU58448/99A priority Critical patent/AU5844899A/en
Publication of WO2000061155A1 publication Critical patent/WO2000061155A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/04—Sulfur, selenium or tellurium; Compounds thereof

Definitions

  • Lactose intolerance which is due to intestinal lactase deficiency, is worldwide in distribution, affecting 50 percent of Orientals, 90 percent of Africans and 30 percent of Caucasians. Lactose intolerance, which varies in seventy from mild to very severe, increases in incidence with increasing age Lactase is a Sulfur-containing enzyme Sulfur, mixed with molasses, has been used as a laxative
  • Serum vitamin B12 and erythrocyte folic acid levels were obtained within the 24 hours immediately preceding the first daily dose of Sublimed Sulfur. A record was kept of the presence or absence of symptoms of lactose intolerance. Exclusion criteria for the study included diarrhea from causes other than milk and milk products. Beta-D-galactosidase was not taken by the patients during the course of the study.
  • a regimen of treatment with Sublimed Sulfur restores lactose tolerance in patients with lactose intolerance.
  • the lactose tolerance persists during treatment with Sublimed Sulfur and after discontinuation of Sublimed Sulfur therapy. Lactose tolerance is restored by Sublimed Sulfur therapy to patients who develop lactose intolerance after discontinuation of Sublimed Sulfur.
  • Table 1 Effects of Sublimed Sulfur on Lactose Intolerance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'intolérance au lactose est due à une carence en lactase. La lactase est une enzyme contenant du soufre. On a utilisé du soufre, mélangé avec des mélasses comme laxatif. L'étude concerne 11 patients, notamment 7 hommes et 4 femmes, présentant une intolérance au lactose sévère depuis plus d'un an. L'absorption de lait et de produits laitiers provoque des diarrhées, des douleurs abdominales, des gonflements, des ballonnement, et des flatulences pendant 15 minutes à 60 minutes. Après confirmation de l'intolérance au lactose à l'aide d'un régime sans lactose pendant une semaine, les patients sont simultanément mis au régime sans lactose, et traités avec 200 mg de soufre sublimé, sous forme d'une gélule administrée oralement deux fois par jour après les repas pendant 15 jours. Après quoi, ils reprennent un régime régulier comprenant du lait et des produits laitiers et continuent à prendre 200mg de soufre sublimé, sous forme d'une gélule administrée oralement deux fois par jour après les repas pendant 30 jours supplémentaires. Les patients ayant la diarrhée pour d'autres causes que celles dues au lait et aux produits laitiers sont exclus de l'étude. Les patients ne prennent pas de Béta-D-galactosidase pendant l'étude. Pendant la troisième semaine de thérapie par le soufre sublimé, les 11 patients ne présentent plus de symptômes de diarrhées, de douleurs abdominales, de gonflements, de ballonnements, et de flatulences, et deviennent tolérants au lactose sans autre traitement. L'un des 11 patients a rechuté après 57 semaines; on a restauré sa tolérance au lactose au moyen d'un autre traitement avec du soufre sublimé; un autre patient a fait une rechute après 14 semaines et n'a pas reçu d'autre traitement. Il n'y a pas eu d'effets secondaires dus à la thérapie avec du soufre sublimé. Un régime de thérapie avec du soufre sublimé restaure la tolérance au lactose chez des sujets présentant une intolérance au lactose sans provoquer d'effets secondaires.
PCT/CA1999/000893 1999-04-08 1999-09-27 Composition, contenant du soufre sublime, permettant de traiter l'intolerance au lactose Ceased WO2000061155A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU58448/99A AU5844899A (en) 1999-04-08 1999-09-27 Composition, containing sublimed sulfur, for the treatment of lactose intolerance

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US12835899P 1999-04-08 1999-04-08
CA 2265921 CA2265921C (fr) 1999-04-08 1999-04-08 Methode de retablissement de la tolerance au lactose chez les personnes ayant une intolerance au lactose
US60/128,358 1999-04-08
CA2,265,921 2000-10-03

Publications (1)

Publication Number Publication Date
WO2000061155A1 true WO2000061155A1 (fr) 2000-10-19

Family

ID=25680848

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CA1999/000893 Ceased WO2000061155A1 (fr) 1999-04-08 1999-09-27 Composition, contenant du soufre sublime, permettant de traiter l'intolerance au lactose

Country Status (2)

Country Link
AU (1) AU5844899A (fr)
WO (1) WO2000061155A1 (fr)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7879363B2 (en) 1998-07-07 2011-02-01 Ritter Pharmaceuticals, Inc. Method for increasing lactose tolerance in mammals exhibiting lactose intolerance
US8486668B2 (en) 2009-02-24 2013-07-16 Ritter Pharmaceuticals, Inc. Prebiotic formulations and methods of use
US8492124B2 (en) 2009-02-24 2013-07-23 Ritter Pharmaceuticals, Inc. Prebiotic formulations and methods of use
US9226933B2 (en) 2004-07-22 2016-01-05 Ritter Pharmaceuticals, Inc. Methods and compositions for treating lactose intolerance

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2228470A1 (en) * 1973-05-09 1974-12-06 Degemont Marguerite Therapeutic compsn. contg. vitamin A, sulphur and live yeast - for treatment of disorders of the ear, nose and throat
US4976970A (en) * 1989-02-24 1990-12-11 Landy Wady N Pharmaceutical composition and method for treatment of digestive disorders
EP0581972A1 (fr) * 1989-02-06 1994-02-09 Verde, Giancarlo U. Composition hemorroidale contenant de la fleur de soufre et de la crème de tatre
EP0615757A1 (fr) * 1993-03-18 1994-09-21 Georges Serge Grimberg Composition thérapeutique nouvelle ayant un effet immunostimulant

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2228470A1 (en) * 1973-05-09 1974-12-06 Degemont Marguerite Therapeutic compsn. contg. vitamin A, sulphur and live yeast - for treatment of disorders of the ear, nose and throat
EP0581972A1 (fr) * 1989-02-06 1994-02-09 Verde, Giancarlo U. Composition hemorroidale contenant de la fleur de soufre et de la crème de tatre
US4976970A (en) * 1989-02-24 1990-12-11 Landy Wady N Pharmaceutical composition and method for treatment of digestive disorders
EP0615757A1 (fr) * 1993-03-18 1994-09-21 Georges Serge Grimberg Composition thérapeutique nouvelle ayant un effet immunostimulant

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7879363B2 (en) 1998-07-07 2011-02-01 Ritter Pharmaceuticals, Inc. Method for increasing lactose tolerance in mammals exhibiting lactose intolerance
US9226933B2 (en) 2004-07-22 2016-01-05 Ritter Pharmaceuticals, Inc. Methods and compositions for treating lactose intolerance
US8486668B2 (en) 2009-02-24 2013-07-16 Ritter Pharmaceuticals, Inc. Prebiotic formulations and methods of use
US8492124B2 (en) 2009-02-24 2013-07-23 Ritter Pharmaceuticals, Inc. Prebiotic formulations and methods of use
US8785160B2 (en) 2009-02-24 2014-07-22 Ritter Pharmaceuticals, Inc. Prebiotic formulations and methods of use
US9579340B2 (en) 2009-02-24 2017-02-28 Ritter Pharmaceuticals, Inc. Prebiotic formulations and methods of use
US9592248B2 (en) 2009-02-24 2017-03-14 Ritter Pharmaceuticals, Inc. Prebiotic formulations and methods of use
US9775860B2 (en) 2009-02-24 2017-10-03 Ritter Pharmaceuticals, Inc. Prebiotic formulations and methods of use
US9808481B2 (en) 2009-02-24 2017-11-07 Ritter Pharmaceuticals, Inc. Prebiotic formulations and methods of use

Also Published As

Publication number Publication date
AU5844899A (en) 2000-11-14

Similar Documents

Publication Publication Date Title
Malek et al. Pediatric nephrolithiasis
Urbancsek et al. Results of a double-blind, randomized study to evaluate the efficacy and safety of Antibiophilus® in patients with radiation-induced diarrhoea
KR100436243B1 (ko) 크립토스포리디오시스성 설사 치료에서의 리팍시민 및 이를함유한 의약 조성물의 용도
CA2338533C (fr) Procede servant a traiter une maladie auto-immune
Anderson et al. Zinc acetate treatment in Wilson's disease
Haas et al. Management of celiac disease
Beazell et al. The influence of alcohol on the digestive tract; a review
JPWO1998015196A1 (ja) 胃切除術後のミネラル補給用組成物
Cohen et al. Fatal hepatic necrosis secondary to isoniazid therapy
Wachstein et al. Disturbance of vitamin B6 metabolism in pregnancy: II. The influence of various amounts of pyridoxine hydrochloride upon the abnormal tryptophane load test in pregnant women
WO2000061155A1 (fr) Composition, contenant du soufre sublime, permettant de traiter l'intolerance au lactose
US5358720A (en) Treatment of arthritic conditions
US6489361B1 (en) Phosphorus binder
Nelis et al. Anorexia, weight loss, and diarrhea as presenting symptoms of angiokeratoma corporis diffusum (Fabry-Anderson's disease)
CA2265921C (fr) Methode de retablissement de la tolerance au lactose chez les personnes ayant une intolerance au lactose
Youssef et al. A comparative study of efficacy, tolerability, and compliance of oral iron preparations for iron deficiency anemia in pregnant women
US5935610A (en) Composition having buffering properties
Buchanan et al. Effectiveness of acarbose, an alpha-glucosidase inhibitor, in uncontrolled non-obese non-insulin dependent diabetes
Czarnecki et al. Generalized morphoea successfully treated with salazopyrine
AU2005210181B2 (en) Composition, comprising L-serine, L-isoleucine, folic acid and trace elements, for treating psoriasis
Martín Rojas-Marcos et al. Severe hypocalcemia following total thyroidectomy after biliopancreatic diversion
FALOON Metabolic effects of nonabsorbable antibacterial agents
Apple et al. The syndrome of inappropriate antidiuretic hormone secretion in multiple sclerosis
AU2023288094A1 (en) Composition of galactooligosaccharides and uses thereof
Freston The pathophysiological and pharmacological basis of peptic ulcer therapy

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 1999945807

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

NENP Non-entry into the national phase

Ref country code: CA

WWR Wipo information: refused in national office

Ref document number: 1999945807

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1999945807

Country of ref document: EP